Maxim Group Downgrades Akari Therapeutics to Hold

Benzinga Newsdesk www.benzinga.com Negative 92.2%

Neg 92.2% Neu 0% Pos 0%

Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.

Comments

No comments yet. Be the first!